drugset / Trial / NCT00660816

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00660816 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Pemetrexed disodium and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving pemetrexed disodium or docetaxel together with erlotinib hydrochloride is more effective than giving pemetrexed disodium or docetaxel alone in treating non-small lung cancer. PURPOSE: This randomized phase II trial is studying how well giving pemetrexed disodium or docetaxel together with or without erlotinib hydrochloride works in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Timeline

Start
2008-01
Primary completion
2013-04
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral
Background Docetaxel Small molecule — Intravenous
Background Pemetrexed Small molecule — Intravenous

Indications